Wednesday, November 16, 2022 3:09:04 PM
$BIXT NEWS - Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in @medrxivpreprint - https://t.co/hEr98kHKRr #gylcotime #galectin #galectin3 #COVID19 #antivirals #longcovid @ChilesResearch @EricTopol @drbeen_medical @EnemyInAState @DrEricDing pic.twitter.com/UopYZdCx5F
— Bioxytran Inc. (@BioxytranInc) November 16, 2022
Major value inflection point for $BIXT like in 2013 when $GILD announced P2 #HCV trial and 19/19 responded. A perfectly designed clinical trial led to HCV cure. #Bioxtran #COVID19 trial 17/17 responders. Major advancement in #Galectin Science & #Glycobiology #Glycovirology pic.twitter.com/ma7T9tDTWr
— Mike Sheikh (@MikeSheikh2) November 16, 2022
Recent BIXT News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
